| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/05/2003 | EP1280905A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene carboxy terminal peptides |
| 02/05/2003 | EP1280857A1 Wound gels |
| 02/05/2003 | EP1280849A1 Process for the preparation of proteinbased hydrogels |
| 02/05/2003 | EP1280840A1 Polyurethane and the use thereof for modifying rheological properties |
| 02/05/2003 | EP1280734A2 Salt comprising more than 95 wt. % of sodium chloride, use and preparation method thereof and method for measuring salt water content |
| 02/05/2003 | EP1280604A1 Media milling |
| 02/05/2003 | EP1280576A2 Dispensing devices and liquid formulations |
| 02/05/2003 | EP1280572A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280570A2 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280569A1 Delivery systems for treatment of vascular disease |
| 02/05/2003 | EP1280568A1 Delivery devices for treatment of vascular disease |
| 02/05/2003 | EP1280566A2 Growth factor modified protein matrices for tissue engineering |
| 02/05/2003 | EP1280559A2 Acylated cyclodextrin guest inclusion complexes |
| 02/05/2003 | EP1280558A2 Semi-solid delivery vehicle and pharmaceutical compositions |
| 02/05/2003 | EP1280557A1 Method for the preparation of polymeric micelle via phase separation of block copolymer |
| 02/05/2003 | EP1280556A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 02/05/2003 | EP1280552A2 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 02/05/2003 | EP1280539A2 Nontoxic vernix compositions and method of producing |
| 02/05/2003 | EP1280538A2 Compositions containing molecular iodine |
| 02/05/2003 | EP1280532A1 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases |
| 02/05/2003 | EP1280531A1 Local anesthetic methods and kits |
| 02/05/2003 | EP1280520A2 Phospholipid-based powders for drug delivery |
| 02/05/2003 | EP1280519A1 Microprojectile delivery system and particulate product |
| 02/05/2003 | EP1280518A2 Liposome drug delivery |
| 02/05/2003 | EP1280517A1 Beta-glucans encapsulated in liposomes |
| 02/05/2003 | EP1280516A1 Method for transdermal or intradermal delivery of molecules |
| 02/05/2003 | EP1280515A2 Pharmaceutical compositions comprising cannabis |
| 02/05/2003 | EP1280512A2 Delivery systems for treatment of vascular disease |
| 02/05/2003 | EP1280507A1 Eutectic mixtures in cosmetic compositions |
| 02/05/2003 | EP1280500A2 Synergistic antiplaque/antigingivitis oral composition |
| 02/05/2003 | EP1280499A2 Polymeric delivery and release systems for oral care actives |
| 02/05/2003 | EP1280496A2 Cosmetic agents containing 2-furanone derivatives |
| 02/05/2003 | EP1280495A2 3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
| 02/05/2003 | EP1280486A1 Minimizing adverse experience associated with oxybutynin therapy |
| 02/05/2003 | EP1280409A1 A gene therapy system and method using alpha-msh and its derivatives |
| 02/05/2003 | EP1223918B1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor |
| 02/05/2003 | EP1196187A4 Keratinocyte growth factor-2 formulations |
| 02/05/2003 | EP1194145B1 Stable xylometazoline and oxymetazoline solution |
| 02/05/2003 | EP1105107A4 Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| 02/05/2003 | EP1051174B1 Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations |
| 02/05/2003 | EP1003486B1 Pharmaceutical compositions containing an effervescent acid-base couple |
| 02/05/2003 | EP0996429B1 Solid state solutions and dispersions of poorly water soluble drugs |
| 02/05/2003 | EP0932391B1 Fusogenic liposome composition and method |
| 02/05/2003 | EP0928611B1 Medical powder |
| 02/05/2003 | CN1395613A 抗微生物组合物 The antimicrobial composition |
| 02/05/2003 | CN1395491A Polymer blends as biodegradable matrices for preparing biocomposites |
| 02/05/2003 | CN1394648A Recombinant basic fibroblast growth factor protection agent |
| 02/05/2003 | CN1394599A Preparation method of medicinal antimony sulfide nano colloidal particles |
| 02/05/2003 | CN1394597A Process for preparing powder preparation |
| 02/05/2003 | CN1100570C Veterinary coposition containing proton pump inhibitor |
| 02/05/2003 | CN1100564C Medicine for treating HIV infection, its composition and its use |
| 02/05/2003 | CN1100538C Lotion |
| 02/05/2003 | CN1100536C Composition for rectal administration |
| 02/04/2003 | WO2002011734A1 Aqueous pharmaceutical compositions |
| 02/04/2003 | US6515105 Vascular Endothelial Growth Factor binding to extracellular domain of NP-1 (Neuropilin-1); bioactive complexes; mediate useful cell responses or antagonize undesired biological activities; angiogenesis; cell differentiation |
| 02/04/2003 | US6515100 Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution |
| 02/04/2003 | US6515022 Use of inhaled retinoids in the treatment of lung diseases |
| 02/04/2003 | US6515017 Polyamino acid conjugated paclitaxel or docetaxel have increased water solubility, efficacy and accumulation within a tumor |
| 02/04/2003 | US6515016 Treating or preventing multiple sclerosis, by administering an antimicrotubule agent; treating various other inflammatory diseases |
| 02/04/2003 | US6515009 Therapeutic inhibitor of vascular smooth muscle cells |
| 02/04/2003 | US6514983 Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase |
| 02/04/2003 | US6514965 Substituted 1-benzazepines and derivatives thereof |
| 02/04/2003 | US6514962 Beta -lactam antibiotic having an esterified carboxy group directly coupled to the nucleus is mixed with a salt of phosphoric acid and oil, a dramatic improvement occurs in its stability |
| 02/04/2003 | US6514958 Dosage unit comprising tibolone and a water insoluble starch product is contained in a humid atmosphere of 50 to 70% relative humidity until administration |
| 02/04/2003 | US6514947 Formulated nucleic acid compositions and methods of administering the same for gene therapy |
| 02/04/2003 | US6514945 Azalide antibiotic compositions |
| 02/04/2003 | US6514943 Method and composition for preserving viruses |
| 02/04/2003 | US6514940 Protected during pasteurization stabilizers (monosaccharides, disaccharides, and oligosaccharides; or amino acids) |
| 02/04/2003 | US6514536 Drug preparations for treating sexual dysfunction |
| 02/04/2003 | US6514535 For drug delivery |
| 02/04/2003 | US6514534 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 02/04/2003 | US6514533 Device for the sustained release of aggregation-stabilized, biologically active agent |
| 02/04/2003 | US6514531 Controlled-release dosage forms comprising zolpidem or a salt thereof |
| 02/04/2003 | US6514526 Coated starch capsules and a process for producing them |
| 02/04/2003 | US6514524 Improved absorption of hydrophilic ingredients because of particular excipients; calcium 3-acetylamino-1-propane sulfonate (calcium acamprosate); polysorbates, fatty ethers or esters of PEG, polyglycolysed glycerides |
| 02/04/2003 | US6514522 Polymer constructs |
| 02/04/2003 | US6514520 Containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts such as disodium EDTA; especially the antihistamines loratadine, descarboethoxyloratadine, and azatadine |
| 02/04/2003 | US6514519 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine; oral administration |
| 02/04/2003 | US6514516 Local anesthetic and a biocompatible controlled release material consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(lactic) acid, poly(glycolic) acid, polyesters, polyorthoesters, proteins, polysaccharides |
| 02/04/2003 | US6514503 Mucosal administration; glyceride, antigen and vehicle |
| 02/04/2003 | US6514498 Modified/chimeric superantigens and their use |
| 02/04/2003 | US6514494 Bacterial strain, processed plant extracts, compostions containing same, processes for their preparation and their therapeutic and industrial applications |
| 02/04/2003 | US6514492 Methacrylic acid polymer crosslinked with divinylbenzene as the carrier; orbifloxacin; |
| 02/04/2003 | US6514491 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 02/04/2003 | US6514489 Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| 02/04/2003 | US6514484 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier |
| 02/04/2003 | US6514481 Magnetic nanoparticles for selective therapy |
| 02/04/2003 | US6514193 Method of administering a therapeutically active substance |
| 02/04/2003 | CA2421787A1 Aqueous pharmaceutical compositions |
| 02/04/2003 | CA2362539C Fluorocarbon aerosol medicaments |
| 02/04/2003 | CA2268967C Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics |
| 02/04/2003 | CA2095633C Enrichment method for variant proteins with altered binding properties |
| 02/03/2003 | CA2393189A1 Non-combustible water-dispersible vitamin compositions |
| 01/30/2003 | WO2003008932A2 Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols |
| 01/30/2003 | WO2003008628A2 Enzymatic nucleic acid peptide conjugates |
| 01/30/2003 | WO2003008555A2 Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| 01/30/2003 | WO2003008495A1 Pullulan-containing powder, process for producing the same and use thereof |
| 01/30/2003 | WO2003008480A1 Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug |
| 01/30/2003 | WO2003008457A2 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | WO2003008454A2 Glycoprotein vi fusion proteins |